# Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)

> **NCT00168012** · PHASE3 · COMPLETED · sponsor: **CSL Behring** · enrollment: 42 (—)

## Conditions studied

- Agammaglobulinemia
- IgG Deficiency
- Common Variable Immunodeficiency

## Interventions

- **DRUG:** Immunoglobulins Intravenous (Human)

## Key facts

- **NCT ID:** NCT00168012
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** —
- **Final completion:** 2005-09
- **Target enrollment:** 42 (—)
- **Last updated:** 2011-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00168012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00168012, "Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00168012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*